Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
MYD88 wild-type ST2825 diffuse large B-cell lymphoma predicted - sensitive detail...
EZH2 Y641N UNC1999 diffuse large B-cell lymphoma sensitive detail...
Unknown unknown Birabresib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Sirolimus + UCN-01 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown IT-901 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown SEL24-B489 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown SEL24-B489 + Ibrutinib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Copanlisib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown INCB050465 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown INCB039110 + INCB050465 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Ublituximab + Umbralisib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown MLN0905 + Rituximab diffuse large B-cell lymphoma not applicable detail...
Unknown unknown MLN0905 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Cerdulatinib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Fostamatinib diffuse large B-cell lymphoma no benefit detail...
Unknown unknown ST7612AA1 diffuse large B-cell lymphoma not applicable detail...
MYD88 act mut eFT508 diffuse large B-cell lymphoma predicted - sensitive detail...
Unknown unknown eFT508 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown CUDC-907 diffuse large B-cell lymphoma not applicable detail...
MYD88 L265P N/A diffuse large B-cell lymphoma not applicable detail...
EZH2 Y641N ACY-957 diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641S ACY-957 diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641N Vorinostat diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641S Vorinostat diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641N ACY-957 + GSK126 diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641S ACY-957 + GSK126 diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641N ACY-957 + DZNeP diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641S ACY-957 + DZNeP diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641S GSK126 diffuse large B-cell lymphoma decreased response detail...
EZH2 Y641N GSK126 diffuse large B-cell lymphoma no benefit detail...
EZH2 Y641S DZNeP diffuse large B-cell lymphoma decreased response detail...
EZH2 Y641N DZNeP diffuse large B-cell lymphoma predicted - sensitive detail...
EZH2 Y641N ACY-957 + Doxorubicin diffuse large B-cell lymphoma sensitive detail...
EZH2 positive Tazemetostat diffuse large B-cell lymphoma predicted - sensitive detail...
Unknown unknown CPI-0610 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown BGB-3111 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown GS-5829 + Venetoclax diffuse large B-cell lymphoma not applicable detail...
Unknown unknown TTI-621 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Abexinostat diffuse large B-cell lymphoma not applicable detail...
MYD88 L265P Vorinostat diffuse large B-cell lymphoma sensitive detail...
Unknown unknown Acalabrutinib + ACP-319 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown AT-7867 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown OPB-111077 diffuse large B-cell lymphoma not applicable detail...
EZH2 Y646F EED226 diffuse large B-cell lymphoma sensitive detail...
EZH2 Y646N EED226 diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641N EED226 diffuse large B-cell lymphoma sensitive detail...
EZH2 Y646S EED226 diffuse large B-cell lymphoma sensitive detail...
EZH2 F120L EZH2 Y111N EI1 diffuse large B-cell lymphoma resistant detail...
EZH2 F120L EZH2 Y111N EED226 diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641N EED226 + EI1 diffuse large B-cell lymphoma sensitive detail...
EZH2 mutant A-395 diffuse large B-cell lymphoma sensitive detail...
Unknown unknown Ibrutinib + Venetoclax diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Fenretinide diffuse large B-cell lymphoma not applicable detail...
Unknown unknown JCAR017 diffuse large B-cell lymphoma not applicable detail...
PTEN loss Idelalisib + MK2206 diffuse large B-cell lymphoma predicted - sensitive detail...
PTEN loss GSK2334470 + Idelalisib diffuse large B-cell lymphoma predicted - sensitive detail...
Unknown unknown Obinutuzumab + CHOP diffuse large B-cell lymphoma no benefit detail...
Unknown unknown Umbralisib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Fostamatinib + Silmitasertib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Ibrutinib + Silmitasertib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Ibrutinib diffuse large B-cell lymphoma not applicable detail...
MYD88 L265P Ibrutinib diffuse large B-cell lymphoma resistant detail...
Unknown unknown SNS-510 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Tisagenlecleucel diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Ibrutinib + PQR309 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown LAM-002A diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Buparlisib + Ibrutinib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown EBI-2511 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Loncastuximab tesirine diffuse large B-cell lymphoma not applicable detail...
Unknown unknown STRO-001 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Hu5F9-G4 + Rituximab diffuse large B-cell lymphoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00001337 Phase II R-EPOCH Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Recruiting
NCT00671112 Phase I Bortezomib + Everolimus Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Terminated
NCT00918463 Phase II Dasatinib A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Terminated
NCT00978432 Phase II Panobinostat + Everolimus Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Terminated
NCT01177397 Phase Ib/II CC-223 Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed
NCT01193842 Phase Ib/II Vorinostat R-EPOCH Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Active, not recruiting
NCT01251575 Phase II Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Recruiting
NCT01307267 Phase I Utomilumab + Rituximab Utomilumab A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Completed
NCT01334502 Phase I Everolimus CHOP + Rituximab Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma Completed
NCT01421524 Phase I CC-122 Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Active, not recruiting
NCT01431209 Phase II Ruxolitinib Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma Active, not recruiting
NCT01449461 Phase Ib/II Brigatinib A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 Active, not recruiting
NCT01453205 Phase II Cisplatin + Cytarabine + Dexamethasone Carboplatin + Etoposide + Ifosfamide Rituximab MEDI-551 A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Completed
NCT01686165 Phase II Belinostat Rituximab Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Completed
NCT01691898 Phase Ib/II Obinutuzumab + Pinatuzumab Vedotin + Rituximab Polatuzumab Vedotin + Pinatuzumab Vedotin + Rituximab Obinutuzumab + Polatuzumab Vedotin A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS) Active, not recruiting
NCT01719250 Phase I Buparlisib Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed
NCT01799889 Phase II Entospletinib A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies Active, not recruiting
NCT01804686 Phase III Ibrutinib A Long-term Extension Study of PCI-32765 (Ibrutinib) Enrolling by invitation
NCT01854606 Phase Ib/II AEB071 + Everolimus Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma Completed
NCT01855750 Phase III Ibrutinib Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Active, not recruiting
NCT01859819 Phase II Cytarabine + Rituximab Treatment for Advanced B-Cell Lymphoma Recruiting
NCT01897012 Phase I romidepsin Alisertib Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas Completed
NCT01938638 Phase I BAY1143572 Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Completed
NCT01953692 Phase I Pembrolizumab A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) Active, not recruiting
NCT01955499 Phase I Ibrutinib + lenalidomide Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Active, not recruiting
NCT01959698 Phase Ib/II Carfilzomib + Rituximab Carboplatin + Etoposide + Ifosfamide Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Recruiting
NCT01992653 Phase I Cyclophosphamide + Doxorubicin + Prednisone Rituximab Polatuzumab Vedotin Obinutuzumab A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma Completed
NCT01994382 Phase I Cerdulatinib Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma Recruiting
NCT02000934 Phase I TAK-659 A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies Active, not recruiting
NCT02029443 Phase Ib/II Acalabrutinib ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia Active, not recruiting
NCT02031419 Phase I CC-122 + CC-292 CC-223 + CC-292 CC-122 + CC-223 Rituximab Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma Active, not recruiting
NCT02055820 Phase I Venetoclax Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Obinutuzumab A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma Active, not recruiting
NCT02061761 Phase Ib/II Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies Recruiting
NCT02073097 Phase Ib/II Carfilzomib + Rituximab Cyclophosphamide + Doxorubicin + Vincristine Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma Recruiting
NCT02077166 Phase Ib/II Rituximab + Lenalidomide + Ibrutinib Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting
NCT02082977 Phase I GSK126 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma Terminated
NCT02106091 Phase I AFM11 Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL Suspended
NCT02138786 Phase II Selinexor Study of Selinexor (KPT-330) in Patients With Refractory and/or Relapsed Richter's Transformation (RT) Terminated
NCT02141451 Phase Ib/II INCB7839 + Rituximab ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL Active, not recruiting
NCT02181218 Phase I Pegfilgrastim romidepsin Gemcitabine + Oxaliplatin + Dexamethasone Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas Active, not recruiting
NCT02203526 Phase I Temozolomide + Etoposide + Doxil + Dexamethasone + Ibrutinib Cytarabine Rituximab Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma Recruiting
NCT02208037 Phase II Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Completed
NCT02219737 Phase I Ibrutinib Carboplatin + Etoposide + Ifosfamide + Rituximab Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Completed
NCT02220842 Phase I Atezolizumab + Obinutuzumab A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma Active, not recruiting
NCT02226965 Phase II PNT2258 Wolverine: PNT2258 for Treatment of Patients With r/r DLBCL Unknown status
NCT02227251 Phase II Selinexor Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SADAL) Active, not recruiting
NCT02229981 Phase Ib/II ABC294640 An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma Withdrawn
NCT02252146 Phase Ib/II IMO-8400 Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88L265P Mutation Completed
NCT02257567 Phase Ib/II Bendamustine + Rituximab Polatuzumab Vedotin Obinutuzumab A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma Recruiting
NCT02282358 Phase Ib/II Mocetinostat Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Active, not recruiting
NCT02303392 Phase I Ibrutinib + Selinexor Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma Recruiting
NCT02315326 Phase Ib/II Ibrutinib Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) Recruiting
NCT02323230 Phase II Cyclophosphamide + DPX-Survivac A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL Unknown status
NCT02327078 Phase Ib/II INCB024360 + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Active, not recruiting
NCT02343536 Phase I Cyclophosphamide + Prednisone + Rituximab + Vincristine Azacitidine A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma Active, not recruiting
NCT02348216 Phase Ib/II KTE-C19 A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) Recruiting
NCT02361346 Phase I MT-3724 PK, PD, Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Non-Hodgkin's B-Cell Lymphoma and B-Cell Chronic Lymphocytic Leukemia (MT-3724NHL001) Recruiting
NCT02362997 Phase II Pembrolizumab Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL Recruiting
NCT02376699 Phase I Pembrolizumab + SEA-CD40 SEA-CD40 Safety Study of SEA-CD40 in Cancer Patients Active, not recruiting
NCT02391116 Phase II Copanlisib Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Completed
NCT02399085 Phase II Lenalidomide + MOR208 A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL Active, not recruiting
NCT02401048 Phase Ib/II Ibrutinib + MEDI4736 A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas Active, not recruiting
NCT02408042 Phase Ib/II Rituximab Carboplatin + Etoposide + Ifosfamide Pembrolizumab Brentuximab vedotin Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) Withdrawn
NCT02420795 Phase Ib/II ONC201 Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma Recruiting
NCT02436707 Phase II Ibrutinib Cisplatin + Dexamethasone + Gemcitabine + Rituximab Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma Recruiting
NCT02440685 Phase Ib/II ASN002 A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Terminated
NCT02443077 Phase III Cyclophosphamide Carmustine + Cytarabine + Etoposide + Melphalan Ibrutinib Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Suspended
NCT02445248 Phase II Tisagenlecleucel Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients (JULIET) Active, not recruiting
NCT02454270 Phase II JNJ-64052781 A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies Terminated
NCT02471911 Phase I Dexamethasone Carboplatin + Etoposide + Ifosfamide + Rituximab Selinexor KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma Recruiting
NCT02516553 Phase I BI 894999 BI 894999 First in Human Dose Finding Study in Advanced Malignancies Recruiting
NCT02530125 Phase II Pidilizumab Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission Terminated
NCT02531308 Phase II Metformin Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Pegfilgrastim Rituximab Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL) Terminated
NCT02532192 Phase I Rituximab Cisplatin Dexamethasone Cytarabine Fluconazole Belinostat A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma Withdrawn
NCT02541565 Phase I Pembrolizumab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Rituximab Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma Recruiting
NCT02543879 Phase I FT-1101 Azacitidine + FT-1101 Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Recruiting
NCT02549651 Phase I Durvalumab + Tremelimumab Durvalumab AZD9150 + Durvalumab MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023) Completed
NCT02564744 Phase II Debio 1562 + Rituximab Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL Recruiting
NCT02570542 Phase II Plerixafor Carmustine + Cytarabine + Etoposide + Melphalan Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting
NCT02572453 Phase II AT13387 AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma Recruiting
NCT02576990 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Primary Mediastinal Large B-cell Lymphoma (MK-3475-170/KEYNOTE-170) Active, not recruiting
NCT02580552 Phase I MRG-106 Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL Recruiting
NCT02581631 Phase Ib/II Brentuximab vedotin + Nivolumab A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436) Recruiting
NCT02589145 Phase Ib/II Lenalidomide Pyridoxine Dexamethasone Busulfan + Melphalan Enoxaparin Rituximab Gemcitabine Vorinostat Palifermin Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype Active, not recruiting
NCT02596971 Phase I Atezolizumab + Obinutuzumab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Bendamustine Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma Active, not recruiting
NCT02600897 Phase Ib/II lenalidomide + Obinutuzumab + Polatuzumab Vedotin A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting
NCT02611323 Phase Ib/II Obinutuzumab + Polatuzumab Vedotin + Venetoclax A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting
NCT02624986 Phase Ib/II Idasanutlin + Obinutuzumab A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Active, not recruiting
NCT02628405 Phase Ib/II R2-ICE R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma Recruiting
NCT02631044 Phase I JCAR017 Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) Recruiting
NCT02636322 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Vincristine Rituximab + Lenalidomide + Ibrutinib Prednisone A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma Recruiting
NCT02650999 Phase Ib/II Pembrolizumab Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas Unknown status
NCT02658968 Phase I Betalutin Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) Recruiting
NCT02674750 Phase II CUDC-907 + Rituximab CUDC-907 Study to Evaluate the Efficacy and Safety of CUDC-907 With and Without Rituximab in Patients With RR MYC-Altered DLBCL Active, not recruiting
NCT02681302 Phase Ib/II Nivolumab + Ipilimumab Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence (CPIT001) Recruiting
NCT02684617 Phase I Dinaciclib + Pembrolizumab Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) (KEYNOTE-155) Recruiting
NCT02698189 Phase I Birabresib A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005) Active, not recruiting
NCT02700022 Phase I Alisertib R-EPOCH A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas Terminated
NCT02701673 Phase Ib/II Azacitidine Pyridoxine Gemcitabine Belinostat Busulfan Melphalan Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma Withdrawn
NCT02706405 Phase I Cyclophosphamide + JCAR014 + MEDI4736 JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Recruiting
NCT02729896 Phase Ib/II Atezolizumab + Obinutuzumab + Polatuzumab Vedotin A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Active, not recruiting
NCT02734771 Phase II Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting
NCT02743546 Phase I Ibrutinib + JNJ-64052781 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma Withdrawn
NCT02756247 Phase I Buparlisib + Ibrutinib A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma Active, not recruiting
NCT02760485 Phase Ib/II Ibrutinib + INCB039110 A Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Recruiting
NCT02763254 Phase II CMD-003 Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas (CIVIC) Terminated
NCT02763319 Phase II Bendamustine + MOR208 Bendamustine + Rituximab A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND) Recruiting
NCT02776813 Phase I ACTR087 + Rituximab Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma Recruiting
NCT02793583 Phase II Umbralisib Ublituximab + Umbralisib Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma (UNITY-DLBCL) Recruiting
NCT02815397 Phase II Metformin DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma Terminated
NCT02874404 Phase II Ibrutinib + Umbralisib TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting
NCT02875002 Phase I Belinostat + Volasertib Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas Withdrawn
NCT02909777 Phase I CUDC-907 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma Recruiting
NCT02914938 Phase I ME-401 ME-401 + Rituximab A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma Recruiting
NCT02926833 Phase Ib/II Atezolizumab + KTE-C19 A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6) Active, not recruiting
NCT02931110 Phase I CBL0137 Study of IV CBL0137 in Previously Treated Hematological Subjects Recruiting
NCT02950220 Phase I Pembrolizumab + Ibrutinib Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Active, not recruiting
NCT02951156 Phase III Avelumab + Azacitidine + Utomilumab Avelumab + Rituximab + Utomilumab Bendamustine + Rituximab Gemcitabine + Oxaliplatin + Rituximab Avelumab + Bendamustine + Rituximab Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) Active, not recruiting
NCT02953509 Phase Ib/II Hu5F9-G4 + Rituximab Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Recruiting
NCT02961816 Phase II Pyridoxine Busulfan + Gemcitabine + Melphalan + Panobinostat Dexamethasone + Filgrastim + Palifermin + Rituximab Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma Withdrawn
NCT02998476 Phase II INCB050465 A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) Active, not recruiting
NCT03003520 Phase II MEDI4736 + R2-CHOP MEDI4736 + Rituximab + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma Active, not recruiting
NCT03015896 Phase Ib/II Lenalidomide + Nivolumab Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Recruiting
NCT03019640 Phase II BEAM + Lenalidomide + Filgrastim + Rituximab Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma Recruiting
NCT03028103 Phase I Tazemetostat + Fluconazole Repaglinide + Omeprazole + Tazemetostat Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects Active, not recruiting
NCT03036904 Phase I Venetoclax + DA-EPOCH-R Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R) Recruiting
NCT03064867 Phase I Venetoclax + Rituximab + Ifosfamide + Carboplatin + Etoposide Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting
NCT03106428 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies Recruiting
NCT03123393 Phase II TAK-659 TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Active, not recruiting
NCT03135262 Phase Ib/II Idasanutlin + Rituximab + Venetoclax Idasanutlin + Obinutuzumab + Venetoclax Idasanutlin + Obinutuzumab + Rituximab + Venetoclax A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting
NCT03136497 Phase I Ibrutinib + Rituximab + Venetoclax A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting
NCT03147885 Phase Ib/II Selinexor Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Recruiting
NCT03150329 Phase I Pembrolizumab + Vorinostat Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma Recruiting
NCT03153462 Expanded access KTE-C19 + Fludarabine phosphate + Cyclophosphamide Axicabtagene Ciloleucel Expanded Access Study Available
NCT03162536 Phase I ARQ 531 Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies Recruiting
NCT03188965 Phase I BAY1895344 First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Recruiting
NCT03189836 Phase I ACTR707 + Rituximab Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma Recruiting
NCT03205046 Phase Ib/II Acalabrutinib + Vistusertib A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies Active, not recruiting
NCT03207867 Phase II PBF-509 + PDR001 A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma Recruiting
NCT03220022 Phase I R-da-EPOCH Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas Recruiting
NCT03255018 Phase II Pembrolizumab Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extra-Nodal Diffuse Large B-cell Lymphomas Recruiting
NCT03255096 Phase I Rituximab + TEN-010 + Venetoclax A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting
NCT03259503 Phase Ib/II Busulfan Olaparib Vorinostat Palifermin Gemcitabine Melphalan Dexamethasone Pyridoxine Rituximab Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas Not yet recruiting
NCT03263026 Phase III CHOP + Rituximab Enzastaurin Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1 Recruiting
NCT03274492 Phase III Polatuzumab Vedotin R-CHP CHOP + Rituximab A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma Recruiting
NCT03283202 Phase Ib/II CC-122 + RCHOP Study of Safety and Efficacy of CC-122 Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors Recruiting
NCT03297424 Phase Ib/II PLX2853 A Study of PLX2853 in Advanced Malignancies. Recruiting
NCT03305445 Phase Ib/II Nivolumab + Ipilimumab Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL Recruiting
NCT03309878 Phase Ib/II Pembrolizumab Mogamulizumab + Pembrolizumab Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Lymphomas Recruiting
NCT03311958 Phase I Nivolumab Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance Recruiting
NCT03316573 Phase II Pembrolizumab A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas Recruiting
NCT03321643 Phase I Atezolizumab + Gemcitabine + Oxaliplatin + Rituximab Atezolizumab + Rituximab Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma Recruiting
NCT03349450 Phase II Pembrolizumab + DPX-Survivac + Cyclophosphamide DPX-Survivac DPX-Survivac and Checkpoint Inhibitor in DLBCL (SPiReL) Recruiting
NCT03357627 Phase I TAK-659 + Venetoclax A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma Recruiting
NCT03365791 Phase II LAG525 PDR001 PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Active, not recruiting
NCT03379493 Phase I Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma Terminated
NCT03391466 Phase III KTE-C19 A Study Evaluating the Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7) Recruiting
NCT03418038 Phase II Dexamethasone Carboplatin + Etoposide + Ifosfamide Carboplatin + Etoposide + Ifosfamide + Rituximab Cisplatin + Cytarabine + Dexamethasone Cisplatin + Dexamethasone + Gemcitabine Rituximab Cytarabine + Dexamethasone + Oxaliplatin Gemcitabine + Oxaliplatin Cisplatin + Cytarabine + Dexamethasone + Rituximab Ascorbic Acid and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma Recruiting
NCT03424122 Phase I Ibrutinib + INCB050465 Bendamustine + INCB050465 + Rituximab INCB050465 + Rituximab INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) Recruiting
NCT03424603 Phase I STRO-001 Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Recruiting
NCT03440567 Phase I Avelumab + Utomilumab + Carboplatin + Etoposide + Ifosfamide + Rituximab Avelumab + Ibrutinib + Rituximab + Utomilumab Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Recruiting
NCT03460977 Phase I PF-06821497 PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Recruiting
NCT03467373 Phase I Tocilizumab Obinutuzumab + CHOP CHOP + Rituximab RO7082859 CHOP + Obinutuzumab + RO7082859 CHOP + Rituximab + RO7082859 A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas Recruiting
NCT03479268 Phase I Ibrutinib + MLN4924 Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma Recruiting
NCT03484819 Phase II Copanlisib + Nivolumab Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma Not yet recruiting
NCT03488251 Phase II Gemcitabine + MT-3724 + Oxaliplatin PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma Recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03547115 Phase I Voruciclib A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies Recruiting
NCT03558750 Phase Ib/II Lenalidomide + Nivolumab + Rituximab Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma Recruiting
NCT03586024 Phase Ib/II Pembrolizumab Phase I/II Study of Pembrolizumab in Patients With Relapsed or Refractory Extranodal NK/T- Cell Lymphoma (ENKTL), Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (EBV-DLBCL) Recruiting
NCT03589469 Phase II Loncastuximab tesirine Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Recruiting
NCT03598608 Phase Ib/II MK-4280 + Pembrolizumab Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) Recruiting
NCT03610724 Phase II Tisagenlecleucel Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (BIANCA) Recruiting
NCT03630159 Phase I Pembrolizumab + Tisagenlecleucel Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients (PORTIA) Recruiting
NCT03671018 Phase I CHOP + Rituximab Cyclophosphamide + Prednisone + Rituximab + Vincristine Bendamustine + Polatuzumab Vedotin + Rituximab Bendamustine + Obinutuzumab BTCT4465A + Polatuzumab Vedotin BTCT4465A Obinutuzumab Tocilizumab A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma Recruiting
NCT03677141 Phase Ib/II Tocilizumab Cyclophosphamide + Doxorubicin + Rituximab + Polatuzumab Vedotin + Prednisone BTCT4465A + Cyclophosphamide + Doxorubicin + Polatuzumab Vedotin + Prednisone BTCT4465A + CHOP A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma Recruiting
NCT03677154 Phase Ib/II BTCT4465A + Tocilizumab A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy Recruiting
NCT03685344 Phase I Durvalumab + Loncastuximab tesirine Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma Recruiting
NCT03696784 Phase I Rimiducid Bendamustine + Fludarabine phosphate + iC9/CAR.19/IL15-Transduced CB-NK Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Not yet recruiting
NCT03703167 Phase I Rituximab + Lenalidomide + Ibrutinib Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) Recruiting
NCT03704714 Phase Ib/II CHOP + Nivolumab + Rituximab Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma Recruiting
NCT03742258 Phase I CHOP + Rituximab + TAK-659 CHOP + Rituximab Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma Recruiting
NCT03797261 Phase I AMG 176 + Venetoclax A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies Recruiting
NCT03876028 Phase I Ibrutinib + Tisagenlecleucel Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients Not yet recruiting